恒瑞医药：HRS-4729注射液获批开展临床试验

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of its self-developed peptide drug HRS-4729 injection, which is expected to commence soon [1] Group 1: Product Development - HRS-4729 injection is a multi-peptide drug that acts as a triple agonist for GLP-1R, GIPR, and GCGR receptors [1] - The triple receptor activation enhances the regulation of glucose and lipid metabolism, appetite suppression, and promotes energy expenditure, fatty acid oxidation, and lipid breakdown, leading to better weight loss and reduction of liver fat compared to dual-target GLP-1R/GIPR [1]